Stem Cell Therapy for Long COVID: Where the Science Stands in 2026

Long COVID — defined broadly as persistent symptoms following SARS-CoV-2 infection lasting more than 12 weeks — affects an estimated 6–10% of people who have had COVID-19. That translates to tens of millions of people worldwide. Yet as of 2026, no treatment has been approved specifically for Long COVID, and options remain limited to symptom management.

Stem cell and cell-based therapies have been studied for Long COVID since 2021, with a growing body of clinical data now available. The picture is more nuanced than early optimism or dismissal — there are real signals of benefit, meaningful limitations in the data, and important distinctions between what has been studied and who was studied.

The REGENECYTE Trial: Strongest Evidence Published in 2026

In January 2026, StemCyte published results of a 30-patient Phase IIa randomized, placebo-controlled trial in eClinicalMedicine (The Lancet) testing cord blood-derived hematopoietic progenitor cells in patients with Long COVID-associated fatigue.

The results were striking: 85% of treated patients achieved complete fatigue resolution at week 26, compared to 20% in the placebo group. Statistically significant improvements were maintained at all measured timepoints — weeks 6, 12, 18, and 26. Only 2 of 20 treated patients (10%) experienced any adverse events, both mild and resolving within an hour.

Following these results, the FDA granted RMAT (Regenerative Medicine Advanced Therapy) designation in October 2024 and cleared an Expanded Access Program (compassionate use) in January 2026. An End-of-Phase 2 meeting with FDA in March 2025 provided guidance toward a pivotal Phase III trial.

This is the most compelling clinical signal in the Long COVID cell therapy space to date. However, it is important to note: 30 patients is a small sample, and the 85% figure — while extraordinary — needs Phase III confirmation before it can be treated as established efficacy. The therapy is currently accessible only via compassionate use in the US while Phase III is being designed.

Mesenchymal Stem Cell Therapy: Three-Year Follow-Up Data

A separate 100-patient randomized controlled trial with a three-year follow-up published in February 2025 examined MSC therapy in patients with severe acute COVID-19 (not classic Long COVID in mild cases). Key findings included:

• Lung CT scan normalization: 46.9% of MSC patients versus 34.5% in placebo
• MSC-treated patients reached CT normalization approximately 15 months earlier on average
• General Health quality-of-life score: 67.0 (MSC) versus 50.0 (placebo), a statistically significant difference
• No tumorigenesis or unexpected safety signals over three years

The limitation here is important: this study enrolled patients with severe acute COVID-19 requiring hospitalization — not the broader Long COVID population that developed persistent symptoms after mild initial illness. Whether these results translate to the typical Long COVID patient profile is an open question that ongoing trials are designed to answer.

Why Mesenchymal Stem Cells May Help in Long COVID

The biological rationale for MSC therapy in Long COVID is well-established. Long COVID is now understood to involve persistent immune dysregulation, chronic low-grade inflammation, potential viral reservoir persistence, and autonomic nervous system disruption. MSCs address several of these mechanisms:

• They suppress dysregulated immune responses through paracrine anti-inflammatory signaling
• They reduce neuroinflammation — relevant to brain fog and cognitive symptoms
• They lower oxidative stress markers (reduced malondialdehyde in clinical studies)
• They can home to damaged tissue sites and promote local repair

These are established mechanisms from extensive prior MSC research — not speculative. What remains uncertain is the magnitude of clinical benefit across the heterogeneous Long COVID population.

What Remains Uncertain

Long COVID is not a single disease — it is a collection of overlapping syndromes including fatigue, cognitive impairment (brain fog), autonomic dysfunction (POTS, dysautonomia), shortness of breath, and post-exertional malaise. Therapies that address one phenotype may not translate to others. The neurological symptoms — brain fog, memory difficulties — remain the least studied in cell therapy trials.

There is also no approved diagnostic biomarker for Long COVID, which makes trial enrollment and outcome measurement challenging. This is why even well-designed trials produce results that are difficult to apply broadly.

At Rakan Clinic Tokyo

At Rakan Clinic Tokyo, patients presenting with post-COVID symptoms who are considering MSC or IV therapy are evaluated individually. The clinic's adipose-derived MSC therapy and IV exosome treatments address systemic inflammation and immune support — mechanisms that are relevant to Long COVID pathophysiology.

We are transparent that Long COVID-specific treatment protocols remain investigational. What we offer is the established MSC therapy framework — with robust safety data — applied thoughtfully to patients whose symptoms may respond to its anti-inflammatory and immunomodulatory effects. We do not promise outcomes that the evidence does not support.

Patients interested in discussing post-COVID recovery at Rakan Clinic should request a consultation, where your specific symptom profile, history, and goals will inform whether and how regenerative approaches fit your situation.